Latest news with #gamma stimulation

National Post

Cognito Therapeutics to Present Five Abstracts at AAIC 2025 Highlighting Spectris™ Treatment in Alzheimer's Disease

Article content CAMBRIDGE, Mass. — Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotection therapies against neurodegenerative diseases, today announced that five abstracts featuring its lead investigational device, Spectris™, have been accepted for presentation at the Alzheimer's Association International Conference (AAIC) 2025, taking place July 27–31 in Toronto, Canada. Article content The presentations will showcase clinical, neurophysiological, and biomarker data supporting Spectris™, an at-home device designed to deliver personalized, sensory-driven gamma stimulation to slow the progression of Alzheimer's disease. Article content Among the highlights is an oral presentation selected by the International Society to Advance Alzheimer's Research and Treatment (ISTAART): Article content Preservation of Neurophysiological Signals and White Matter with 40Hz Sensory Stimulation in Alzheimer's Disease Session: ISTAART Oral Session Presenter: Chandran Seshagiri, PhD Date/Time: Saturday, July 26, 2025, 10:15–11:15 AM Article content In addition, Cognito will present five poster sessions: Article content 'These presentations underscore the broad neuroprotective potential of Spectris, from preserving white matter and functional connectivity to measuring real-world benefits that matter to patients,' said Ralph Kern, MD, MHSc, Chief Medical Officer of Cognito Therapeutics. 'We look forward to sharing these latest insights with the global neuroscience community at AAIC.' Article content Spectris™ is currently being evaluated in the ongoing HOPE pivotal clinical trial (NCT05637801) for Alzheimer's disease. It is an investigational device and has not yet received regulatory approval for commercial use from the U.S. Food and Drug Administration or any other health authority. Article content About Cognito Therapeutics Article content Cognito Therapeutics is a late clinical-stage medical device company pioneering neuroprotective therapies to address the unmet needs of patients living with CNS disorders. Its lead product, Spectris™ AD, is an at-home therapeutic device that uses non-invasive, sensory-driven neurostimulation to evoke gamma frequency brain activity. The company's feasibility studies have shown the potential for Spectris AD to preserve cognition, daily function, and slow brain atrophy in patients diagnosed with mild-to-moderate AD. Cognito is headquartered in Cambridge, MA. For more information, visit and follow @cognitotx. Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content Kimberly Ha Article content Article content Article content